Starpharma investor webinar – DEP HER2-Lu preclinical data, clinical pathway and opportunity

Starpharma investor webinar – DEP HER2-Lu preclinical data, clinical pathway and opportunity

Starpharma — 2 videos in collection

More on this equity

Starpharma held an investor webinar to present the preclinical data for its DEP HER2-targeted radiotherapy candidate, DEP HER2-Lutetium (DEP HER2-Lu). Starpharma’s chief executive officer, Cheryl Maley, and chief scientific and regulatory officer, Dr Jeremy Paull, discussed the DEP HER2-Lu data, the planned pathway towards a first-in-human Phase 1 study and the broader opportunity for Starpharma’s DEP platform in radiotheranostics. Key opinion leader Professor Tony Lahoutte, whose expertise includes nanobody-based imaging and radionuclide therapy, also shared his perspective.


You may also be interested in these:

Healthcare

Starpharma – executive interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.